SYNB1353
- Generic Name
- SYNB1353
- Drug Type
- Biotech
- Background
SYNB1353 is a strain of the probiotic bacteria Escherichia coli (E. coli) type Nissle and an engineered probiotic drug. Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath